title: Efficacy and safety of intravenous iron therapy for HCV-positive haemodialysis patients.
abstract: BACKGROUND
  Iron supplementation is the cornerstone of anaemia management in haemodialysis (HD) patients. However, efficacy and safety of intravenous (IV) iron therapy in hepatitis C virus (HCV)-positive HD patients is yet to be elucidated.
  
  
  METHODS
  Sixty-six maintenance HD patients with suboptimal response to recombinant human erythropoietin (rh-EPO) were administered IV iron. Each patient received 100 mg/session IV iron sucrose for ten consecutive HD sessions and then the dose was decreased to 50-100 mg weekly or biweekly. Patients were followed for haemoglobin (Hb), ferritin, rh-EPO dose requirements, transaminase levels, and adverse drug reactions.
  
  
  RESULTS
  Baseline demographic and clinical characteristics, as well as Hb, ferritin, transaminase levels, rh-EPO and iron doses were similar between HCV-positive (n = 32) and HCV-negative patients (n = 29). After 5 months of follow-up, a significant increase in ferritin and Hb levels and decrease in rh-EPO doses were observed in both groups. The incidence of adverse drug reactions was not associated with HCV serology. Significant elevation in both alanine and aspartate aminotransferase levels were detected in HCV-positive patients.
  
  
  CONCLUSIONS
  This study has shown that IV iron administration reverses suboptimal response to rh-EPO administration in HD patients regardless of HCV serology. There is however subtle increase of transaminase levels in HCV-positive patients. Further studies are warranted to reveal the impact of variation in serum transaminase levels during IV iron administration in HCV-positive HD patients.
authors.affiliation: Department of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. drserkan@hacettepe.edu.tr
authors.forename: Serkan
authors.initials: S
authors.lastname: Kahraman
authors.forename: Rahmi
authors.initials: R
authors.lastname: Yilmaz
authors.forename: Gultekin
authors.initials: G
authors.lastname: Genctoy
authors.forename: Mustafa
authors.initials: M
authors.lastname: Arici
authors.forename: Bulent
authors.initials: B
authors.lastname: Altun
authors.forename: Yunus
authors.initials: Y
authors.lastname: Erdem
authors.forename: Unal
authors.initials: U
authors.lastname: Yasavul
authors.forename: Cetin
authors.initials: C
authors.lastname: Turgan
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000740:Anemia / Q000188:drug therapy* / Q000821:virology; D001219:Aspartate Aminotransferases / Q000097:blood; D015331:Cohort Studies; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase